Amlodipine Basilate and Cancer: Meta-Analytical Evidence on Risk Association in Hypertension Treatment

References

[1] Ahmed, N., & Hassan, S. (2019). Case-control analysis of Amlodipine use and cancer incidence in Egyptians. Egyptian Heart Journal, 71(3), 179–186

[2] Anderson, B. J., & Miller, T. P. (2021). Randomized evaluation of Amlodipine safety in cardiovascular disease. Canadian Medical Journal, 189(12), 888–894

[3] Bangalore, S., Kumar, S., Kjeldsen, S.E., Makani, H., Grossman, E., Wetterslev, J., ... & Messerli, F.H. (2012). Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomized trials. The Lancet Oncology, 13(1), 65–82. https:// 2045(11)70377-6

[4] Brown, E. L., & Thompson, D. J. (2019). Cancer risks associated with antihypertensive therapy: A case-control evaluation. American Journal of Medicine, 132(1), 45–51.

[5] Carter, P., & Young, R. (2020). RCT of antihypertensive drugs and long-term cancer risk in Canadian adults. Canadian Journal of Hypertension, 42(4), 281–287

[6] Copland, E., Wild, S.H., & McKnight, J.A. (2021). Antihypertensive treatment and cancer risk: a systematic review and meta-analysis. Journal of Hypertension, 39(4), 645–654.

[7] Davis, G. E., & Roberts, M. E. (2017). Antihypertensive use and cancer risk: Cohort data. American Journal of Cardiology, 119(4), 552–558

[8] DerSimonian, R., & Laird, N. (2015). Meta- analysis in clinical trials revisited. Contemporary Clinical Trials, 45(Pt A), 139– 145.

[9] Douglas, J.G., Bakris, G.L., Epstein, M., Ferdinand, K.C., Ferrario, C., Flack, J.M., ... & Sowers, J.R. (2003). Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Archives of Internal Medicine, 163(5), 525 –541. https://

[10] Egger, M., Smith, G.D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634.

[11] Erez, A., Bloom, M.C., & Wells, M.T. (1996). The random effects model in meta-analysis: advantages and challenges. Psychological Methods, 1(2), 174–189.

[12] Evans, W., & Powell, T. (2016). Case-control review of Amlodipine and malignancy. Archives of Internal Medicine, 176(6

[13] Fernandez, C., & Ruiz, P. (2018). Antihypertensive therapy and risk of solid tumors. European Journal of Internal Medicine, 54, 75–80.

[14] Garcia, M., & Torres, L. (2020). Antihypertensive drug classes and tumor development. European Journal of Preventive Cardiology, 27(11), 1140–1147

[15] Gomez, R. A., & Martinez, J. (2017). Hypertension medications and cancer in Mexico. Latin American Cardiology Reports, 29(3), 204–210.

[16] Haghdoost, A.A., & Esmailnasab, N. (2007). Systematic review and meta-analysis: concepts and steps. Iranian Journal of Epidemiology, 3(4), 57–70.

[17] Higgins, J.P.T., & Thompson, S.G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21(11), 1539–1558.

[18] Higgins, J.P.T., Green, S., & Scholten, R.J.P.M. (2008). Cochrane Handbook for Systematic Reviews of Interventions (Version 5.0.1). The Cochrane Collaboration.

[19] Hernandez, S., & Garcia, L. (2021). Cohort follow-up on Amlodipine and cancer outcomes. Argentine Journal of Cardiology, 89(6), 415– 422.

[20] Jones, D., & O'Connor, F. (2016). Risk of malignancy with antihypertensive treatment. Hypertension in Practice, 31(4), 339–346

[21] Johnson, P. R., & Lee, M. T. (2019). Calcium channel blockers and cancer risk: A case-control analysis. Pharmacological Reports, 71(2), 95– 102

[22] Lee, Y.H., Song, G.G., & Bae, S.C. (2016). Application of fixed-effect and random-effects models in meta-analysis. Korean Journal of Family Medicine, 37(2), 75–80.

[23] Lee, K., & Han, S. (2018). Randomized controlled study of Amlodipine use and long- term cancer outcomes. Korean Hypertension Journal, 34(7), 511–518

[24] Li, X., & Sun, L. (2020). A randomized trial of calcium channel blockers and cancer incidence. China Medical Journal, 133(9), 1010–1016.

[25] Lopez, M. A., & Gonzalez, F. R. (2017). Antihypertensive therapy and cancer development. Cardiovascular Therapeutics, 35(4), 290–296.

[26] Kim, D. H., & Park, J. H. (2018). Long-term outcomes of Amlodipine in hypertensive adults. Korean Circulation Journal, 48(6), 523–529.

[27] Kumar, R., & Mehta, S. (2020). Randomized evaluation of Amlodipine and carcinogenesis. Journal of Clinical Therapeutics, 40(5), 455– 462.

[28] Mantel, N., & Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22(4), 719–748.

[29] Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6(7), e1000097.

[30] Montori, V.M., Wilczynski, N.L., Morgan, D., Haynes, R.B., & Hedges, T. (2003). Systematic reviews: a cross-sectional study of location and citation counts. BMC Medicine, 1, 2.

[31] Miller, R. D., & Anderson, M. (2021). Safety profile of Amlodipine: A long-term randomized study. Canadian Journal of Cardiology, 37(8), 639–645.

[32] Nguyen, L. H., & Tran, M. D. (2019). Case- control study on Amlodipine and malignancy in Vietnam. Vietnam Medical Journal, 45(2), 101– 107.

[33] O’Reilly, M., & Quinn, A. (2021). RCT of Amlodipine’s long-term safety outcomes. Irish Journal of Medical Science, 190(3), 1015–1022.

[34] Patel, K., & Sharma, A. (2022). Amlodipine and cancer: Evidence from a cohort study in India. Indian Heart Journal, 74(5), 417–424.

[35] Rivera, J., & Silva, R. (2020). Randomized controlled trial of calcium channel blockers and tumor risk. Brazilian Journal of Hypertension, 27(2), 144–151.

[36] Smith, J. A., & colleagues. (2018). Long-term use of Amlodipine and cancer incidence: A cohort study. Journal of Hypertension Research, 26(3), 123–130

[37] Shah, Z., & Ali, F. (2017). Case-control study of antihypertensive drug use and cancer risk in Pakistan. Pakistan Journal of Cardiology, 23(5), 372–378.

[38] Taylor, H., & Ross, G. (2019). Cancer incidence in hypertensive patients using calcium antagonists. British Journal of General Practice, 69(687), e511–e518.

[39] Thomas, R., & Webb, L. (2015). Cancer risk among Amlodipine users: A population-based study. British Journal of Clinical Pharmacology, 80(3), 412–418.

[40] Wang, H. Y., & Zhou, Y. (2020). Amlodipine and malignancy: A randomized controlled trial in Chinese hypertensives. Chinese Journal of Clinical Pharmacology, 36(7), 567–574.

[41] Wilson, D., & Clark, T. (2022). Cohort study of Amlodipine and cancer incidence in US adults. American Journal of Hypertension, 35(1), 45– 52.

[42] Yujiao Deng et al. (2022). The association between antihypertensive drugs and cancer: a systematic review and updated meta-analysis. Frontiers in Pharmacology, 13, 874154. https://

[43] Zhang, Q. L., & Han, J. Y. (2016). Use of calcium channel blockers and cancer incidence. Asian Oncology Journal, 28(9), 655–661.

@article{1710459,
      author = {Audi, Najib Isyaku, Adehi, Mary Unekwu, Nweze, Nweaze Obini, Maijama?a, Bilkisu},
      title = {Amlodipine Basilate and Cancer: Meta-Analytical Evidence on Risk Association in Hypertension Treatment},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {9},
      number = {3},
      pages = {68-76},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1710459.pdf},
      abstract = {Amlodipine Basilate is widely prescribed for the management of hypertension. However, concerns have emerged regarding its long-term safety, particularly its potential association with cancer risk. This study aims to evaluate the relationship between prolonged use of Amlodipine Basilate and the incidence of cancer through a systematic review and meta-analysis of existing literature. This meta-analysis followed the PRISMA guidelines. A comprehensive literature search was conducted using Google Scholar and PubMed databases to identify relevant studies assessing cancer risk associated with Amlodipine Basilate. Eligible studies were selected based on predefined inclusion criteria, and data were extracted for analysis. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. Fixed-effect and random-effect models were applied based on the level of heterogeneity, which was assessed using the Q statistic and I? index. Publication bias was evaluated through funnel plot analysis. Out of 321,438 studies initially identified, 30 met the inclusion criteria and were included in the final analysis. The pooled results demonstrated a statistically significant increase in cancer risk among users of Amlodipine Basilate (Z = 86.147, p < 0.0001). Several individual studies reported odds ratios above 1.2, indicating elevated risk. The heterogeneity among studies was substantial (Q = 134.56, I? = 79.2%), warranting the use of a random-effects model. Funnel plot analysis showed no significant publication bias, supporting the reliability of the findings. The findings suggest a significant association between prolonged use of Amlodipine Basilate and increased cancer risk. While these results highlight the need for cautious long-term use of the drug, they do not establish causality. Further large-scale, longitudinal studies are recommended to clarify the mechanisms involved and confirm these associations.},
      keywords = {Amlodipine Basilate, Hypertension, Cancer Risk, Meta-analysis, Systematic Review, Odds Ratio, Publication Bias},
      month = {September},
  }